Opinion|Videos|January 10, 2025
Expert Insights: How Tafasitamab + R2 May Impact Clinical Practice in R/R FL
Panelists discuss the potential impact of tafasitamab + R2 on clinical practice in relapsed/refractory follicular lymphoma, including initial thoughts on the combination of CD19 and CD20 in a phase 3 trial, identification of ideal patient candidates, and potential challenges or toxicity risks associated with this triplet regimen.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- This is the first time a CD19 has been combined with a CD20 in a phase 3 trial with positive results. What are your initial thoughts?
- Which r/r FL patients would be the ideal candidate for this new tafasitamab + R2?
- Are there any potential challenges or concerns with utilizing a triplet regimen with tafasitamab? Is there a risk for potential additional toxicities?
Advertisement
Related to this article
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.
New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5